Reading Time: 7 minutesIn a decision rendered by Singapore’s High Court on 20 December 2017, the High Court allowed an application by Novartis (Singapore) Pte Ltd (commenced under Section 44(1) of the Patents Act) and reversed the Registrar’s decision to grant correction to the Register in respect of corrections to priority application number of Bristol-Myers Squibb Pharma Company’s […]